top of page
RRMM
2022 - (R) NCT05347485
Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
2021 - (R) NCT05000450
Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
2021 - (R) NCT04975399
Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
2021 - (R) NCT04756726
Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
2020 - (R) NCT04394650
Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
2020 - (R) NCT04093596
Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
2019 - (R) NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - (R) NCT04108195
Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
2019 - (R) NCT04036461
Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM
2019 - (Active) NCT04083534
Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
2018 - (R) NCT03761108
Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
2018 - (R) NCT03732703
Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
2018 - (R) NCT03651128
Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
2018 - (R) NCT03601078
Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
2018 - (R) NCT03399799
Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
2018 - (Active) NCT03548207
Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
2017 - (R) NCT03309111
Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With RRMM
2017 - (R) NCT03287908
Phase 1/2: AMG 701 Montherapy With Pomalidomide +/- Dex in Relapsed Multiple Myeloma
2017 - (R) NCT03275103
Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
2017 - (R) NCT03145181
Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
2016 - (R) NCT02773030
Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM